SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.

Abstract

Authors

• Amar U Kishan
  Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
• Pin-Chieh Wang
  Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
• Shrinivasa K Upadhyaya
  Department of Biological and Agricultural Engineering, University of California, Davis, Davis, California.
• Henrik Hauswald
  Department of Radiation Oncology and Radiation Therapy, Heidelberg University Hospital, Heidelberg, Germany.
• D Jeffrey Demanes
  Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
• Nicholas G Nickols
  Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; Department of Radiation Oncology, Stanford University, Stanford, California.
• Mitchell Kamrava
  Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
• Ahmad Sadeghi
  Department of Radiation Oncology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California.
• Patrick A Kupelian
  Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
• Michael L Steinberg
  Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California.
• Nicolas D Prionas
  Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California.
• Mark K Buyyounouski
  Department of Radiation Oncology, Stanford University, Stanford, California.
• Christopher R King
  Department of Anesthesiology, Washington University in St Louis, St Louis, MO, 63110, USA.

Keywords

External Resources